Proactive Investors - Run By Investors For Investors

Admiral Group Plc boosted by big Nomura upgrade

Admiral Group Plc boosted by big Nomura upgrade

Admiral Group Plc (LON:ADM) was the subject of a big upgrade today as Nomura moved to ‘buy’, from ‘hold’, and lifted its price target to £23.25 from £16.30.

The broker is positive on the European general (or non-life) insurance sector which Nomura describes as ‘still very special’.

A ‘buy’ recommendation was also repeated for RSA Insurance Group Plc (LON:RSA), and Nomura’s target moved to 510p from 495p.

“As expected, the UK non-life names have performed well on a relative basis year to date amid market turbulence,” Nomura analyst Fahad Changazi said in a note.

“However, strong results by RSA, Direct Line and Admiral, and subsequent strong share price performance on the day, served to highlight the bottom-up attractiveness of UK non-life stocks.”

Commenting specifically on Admiral, Changazi added: “Our two key reasons for upgrading Admiral are exposure to rising UK motor rates and potential to pay out excess capital return above guidance (£300m vs £150-200m guidance).”

Elsewhere, Citigroup spliced 35p off its price target for Barclays Plc (LON:BARC) - and the broker’s ‘buy’ now targets 200p per share.

Investec cooled on engineering group Meggit Plc (LON:MGGT) which it now rates as ‘add’ rather than ‘buy’.

Meanwhile, Liberum Capital downgraded Kurdistan oil producer Genel Energy Plc (LON:GENL) to ‘hold’ from ‘buy’. And, also downgraded African airline Fastjet Plc (LON:FJET) to ‘hold’ from ‘buy’ as well.

Hay fever vaccine specialist Allergy Therapeutics PLC’s (LON:AGY) mix of continued commercial traction and breadth of new product opportunities underpins the investment case, according to Panmure Gordon.

A target price of 51p gives strong upside against current levels and a placing in November has given it the firepower to acquire/license additional products. Buy says the broker.


Register here to be notified of future ADM Company articles

No investment advice: The Company is a publisher and is not registered with or authorised by the Financial Services Authority (FSA). You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Copyright ©, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use